Vir Biotechnology, Inc. (NASDAQ: VIR) announced a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO‑XTEN dual‑masked T‑cell engager (TCE) development candidates targeting selected solid tumor‑associated antigens, with Gilead holding an exclusive license to develop and commercialize the resulting TCEs. Under the agreement, Vir is eligible for up to USD 135 million in upfront and near‑term preclinical payments and up to USD 1.74 billion in further milestones, plus tiered royalties.
Deal Snapshot
| Item | Detail |
|---|---|
| Parties | Vir Biotechnology, Inc. (Nasdaq: VIR) and Gilead Sciences |
| Structure | Collaboration and license agreement |
| Scope | Discovery and engineering of 3 novel PRO‑XTEN dual‑masked TCE development candidates |
| Targets | Selected solid tumor‑associated antigens (not disclosed) |
| Upfront & Near‑Term Payments | Up to USD 135 million |
| Upfront Consideration | USD 90 million – comprising USD 65 million cash + USD 25 million equity investment at a 30 % premium |
| Near‑Term Preclinical Milestones | Up to USD 45 million |
| Further Milestones | Up to USD 1.74 billion (development, regulatory, commercial) |
| Royalties | Tiered high single‑digit to low double‑digit on net sales |
Technology Profile
- Platform: Vir’s proprietary dAIsY (data AI structure and antibodY) platform, enabling rapid, multiparameter optimization of high‑quality TCEs.
- Masking Technology: The universal PRO‑XTEN masking technology, applied here in a dual‑masked configuration designed to deliver a wide therapeutic index – a key limitation for conventional TCEs in solid tumors.
- Design Goal: Next‑generation TCEs, each with potent anti‑tumor activity across solid tumor targets addressing areas of high unmet need.
- Company Expertise: Vir brings deep expertise in TCE discovery and protein engineering to the collaboration.
Roles & Responsibilities
- Vir Biotechnology: Responsible for discovery, design and optimization of the three PRO‑XTEN dual‑masked TCE development candidates.
- Gilead: Holds the exclusive license to nominate and advance candidates generated under the collaboration, and is responsible for subsequent development, manufacturing and commercialization.
Market Impact & Outlook
- Strategic Fit for Gilead: The deal extends Gilead’s cell‑therapy‑adjacent footprint into off‑the‑shelf TCEs for solid tumors, complementing its existing oncology franchise.
- Pipeline Diversification for Vir: Upfront cash and a 30 %‑premium equity investment strengthen Vir’s balance sheet while validating its dAIsY and PRO‑XTEN platforms.
- Solid Tumor TCE Challenge: T‑cell engagers have transformed hematologic oncology but face toxicity and tumor‑penetration hurdles in solid tumors – the dual‑masked PRO‑XTEN approach is designed to widen the therapeutic window.
- Candidate Selection: Which of the three candidates Gilead nominates, and on what timeline, remains subject to collaboration progress; specific targets have not been disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Vir Biotechnology–Gilead collaboration, including candidate discovery, milestone achievement, clinical development, regulatory outcomes, and commercialization expectations. Actual results may differ materially due to risks including scientific and technical execution, regulatory decisions, milestone conditions, and competitive dynamics in the oncology market.-Fineline Info & Tech
